Boswellia (AKBA) vs Dermorphin
A side-by-side research comparison of Boswellia (AKBA) and Dermorphin across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Boswellia (AKBA) | Dermorphin |
|---|---|---|
| Full name | Boswellia Serrata Extract (AKBA) | Dermorphin (Opioid Heptapeptide) |
| Category | Pain & Inflammation | Pain & Inflammation |
| Status | OTC supplement | Research compound |
| Mechanism | AKBA (acetyl-11-keto-beta-boswellic acid) selectively inhibits 5-lipoxygenase (5-LOX), reducing pro-inflammatory leukotrienes. This targets a different inflammatory pathway than NSAIDs (which act on COX), sparing the stomach lining. | Binds mu-opioid receptors with very high affinity and selectivity, producing potent analgesia. Its unusual D-alanine residue makes it resistant to breakdown, contributing to a much stronger effect than morphine on a per-weight basis. |
| Molecular weight | 512.7 Da (AKBA) | 803.9 Da |
| Half-life | ~6 hours (AKBA) | Short (peptide) |
| Bioavailability | Low; improved by AKBA-standardized and phytosome forms | Injection (research) |
| Typical dose | 100-250 mg AKBA-standardized, 1-2x daily | Not established for human use |
| Frequency | 1-2x daily | Research only |
| Route | Oral capsule | Injection (research) |
Boswellia (AKBA) reported benefits
- Reduces joint pain and stiffness
- Non-NSAID (stomach-sparing) anti-inflammatory
- Supports gut inflammation (IBD research)
- Cartilage protection
- Anti-inflammatory via 5-LOX inhibition
Dermorphin reported benefits
- Potent analgesia (research context)
- High mu-opioid receptor selectivity (research interest)
Related comparisons
Research and educational reference only. Not medical advice.